Novartis: lung cancer drug trial fails

(CercleFinance.com) - Novartis said the Phase III CANOPY-A study, which evaluates canakinumab as an adjuvant treatment for non-small cell lung cancer, has failed to meet its primary endpoint of progression-free survival in patients with stages II-IIIA and IIIB.


The Swiss healthcare group said that no new safety signals were observed, and that data from the 1,382-patient study will be presented at an upcoming medical meeting.

The group said that it will pursue new treatment options for patients living with lung cancer, whose needs remain urgent and significant.


Copyright (c) 2022 CercleFinance.com. All rights reserved.